Company Encyclopedia
View More
name
Kanghua Biological
300841.SZ
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines.
1.601 T
300841.SZMarket value -Rank by Market Cap -/-

Financial Score

07/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking37/79
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE5.22%C
    • Profit Margin15.01%A
    • Gross Margin91.64%A
  • Growth ScoreE
    • Revenue YoY-26.47%E
    • Net Profit YoY-66.70%D
    • Total Assets YoY-0.34%D
    • Net Assets YoY1.50%C
  • Cash ScoreD
    • Cash Flow Margin666.20%C
    • OCF YoY-26.47%E
  • Operating ScoreD
    • Turnover0.31D
  • Debt ScoreA
    • Gearing Ratio10.94%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Kanghua Biological released its performance for the first three quarters, with a net profit attributable to the parent company of 189 million yuan, a decrease of 53.41%

    According to the Zhitong Finance APP, Kanghua Biological released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 840 million yuan, a year-on-year decrease of 20.78%. The net profit attributable to shareholders of the listed company was 189 million yuan, a year-on-year decrease of 53.41%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 183 million yuan, a year-on-year decrease of 55.57%. The basic earnings per share were 1.4553 yuan

    Zhitong·
    SZ
    300841
    +1.18%
    Zhitong·
    SZ
    300841
    +1.18%

    Kanghua Biological: The conversion of construction projects to fixed assets will be strictly executed in accordance with relevant regulations

    Kanghua Biological stated on the interactive platform on the 15th in response to investor inquiries that the company's construction projects are transferred to fixed assets in strict accordance with corporate accounting standards and relevant regulations, and the transfer is processed in a timely manner based on the specific construction progress of the project and the conditions for reaching the predetermined usable state. The vaccine production expansion project of Kanghua Biological is currently in the review stage of the supplementary application for drug production licensing, and the project will enhance the production capacity of the company's core product, lyophilized human rabies vaccine, after it goes into production

    Zhitong·
    SZ
    300841
    +1.18%
    Zhitong·
    SZ
    300841
    +1.18%

    Kanghua Biological released its performance for the first half of the year, with a net profit attributable to the parent company of 115 million yuan, a year-on-year decrease of 62.64%

    Kanghua Biological released its 2025 semi-annual report, with operating revenue of 484 million yuan, a year-on-year decrease of 34.70%; net profit attributable to the parent company of 115 million yuan, a year-on-year decrease of 62.64%; net profit excluding non-recurring gains and losses of 112 million yuan, a year-on-year decrease of 63.88%; basic earnings per share of 0.8813 yuan

    Zhitong·
    SZ
    300841
    +1.18%
    Zhitong·
    SZ
    300841
    +1.18%

    Three major driving forces continue the trend of local state-owned assets acquiring listed companies

    Since the beginning of this year, local state-owned assets have launched a wave of acquisitions of listed companies, with industrial merger and acquisition funds and state-owned venture capital platforms becoming the main forces. The biomedical merger and acquisition fund under Shanghai State-owned Assets intends to invest 1.851 billion yuan to take a controlling stake in Kanghua Biological and acquire shares in MICROPORT. The state-owned platforms in Hubei and Anhui are also actively acquiring listed companies. Industry insiders point out that the three main motivations for local state-owned asset mergers and acquisitions include policy encouragement, new leverage for attracting investment, and industrial integration and upgrading

    Wallstreetcn·
    HK
    00853
    -4.38%
    SZ
    300841
    +1.18%
    Wallstreetcn·
    HK
    00853
    -4.38%
    SZ
    300841
    +1.18%

    Kanghua Biological Products' Shareholder To Unload Stake In Co

    Chengdu Kanghua Biological Products Co Ltd :SAYS SHAREHOLDER PLANS TO UNLOAD UP TO 3% STAKE IN CO

    Reuters·
    SZ
    300841
    +1.18%
    Reuters·
    SZ
    300841
    +1.18%